Sofosbuvir Earns FDA Approval as Hepatitis C Treatment

The FDA recently approved sofosbuvir as a once-daily oral treatment for hepatitis C, according to a Gastroenterology & Endoscopy News report.  

Sofosbuvir is a nucleotide analog polymerase inhibitor, the first FDA-approved all-oral treatment for patients with HCV genotypes 2 or 3.

The drug received approval shortly after simeprevir, an Olysio, Janssen Therapeutics drug for patients with HCV genotype 1.

Sofosbuvir is a product of Gilead Sciences.

More Articles on Supply Chain:
FDA Gives 510(k) Clearance to Therapy Cool Flex Ablation Catheter
FDA Issues Draft Guidance on Custom Device Exemption Implementation
FDA Approves First Gel Sealant for Leaking Cornea After Cataract Surgery

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars